We're making the next batch
Ships in ~7 days or less
These products are for laboratory research only and not intended for medical use. They must be handled by qualified professionals in controlled laboratory environments. This compound has not been evaluated by the FDA and is not approved for human or veterinary use.
Third-party tested for purity, identity, and quantity.
Research-grade PT-141 (Bremelanotide) is typically supplied as a lyophilized white to off-white powder with a purity of ≥98% as determined by reverse-phase HPLC analysis. Each lot is accompanied by a certificate of analysis (CoA) detailing HPLC purity, mass spectrometric confirmation of molecular weight (MW ≈ 1025.18 g/mol), and net peptide content.
Published research has characterized PT-141 activity primarily at melanocortin receptor subtypes MC3R and MC4R using recombinant expression systems (e.g., HEK-293, CHO cells), cAMP accumulation assays, and radioligand competitive binding assays. Additional in vitro models include primary neuronal cultures and hypothalamic tissue preparations used to investigate downstream signaling events. MC1R and MC5R binding affinity is comparatively low, making PT-141 a useful tool for MC3R/MC4R-selective research.
No. PT-141 supplied by this company is a research chemical intended strictly for in vitro laboratory and preclinical research use only. It is not intended for, nor approved for, human consumption, self-administration, veterinary use, or any clinical application outside formally authorized and regulated clinical trial settings. Researchers must comply with all applicable institutional, national, and local regulations governing the use of research peptides.
PT-141 (Bremelanotide) differs from Melanotan II (MT-II) primarily in the C-terminal modification: PT-141 bears a free carboxylic acid terminus rather than the C-terminal amide present in MT-II. This structural difference alters metabolic stability, receptor binding kinetics, and pharmacokinetic profile in preclinical models. Both are cyclic heptapeptides incorporating a His-Phe-Arg-Trp pharmacophore critical for melanocortin receptor engagement, but these terminal differences are the basis of ongoing SAR research.
Quality controlled from start to finish. No outsourcing.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin-receptor agonist derived from the α-MSH analog melanotan II. It acts at melanocortin receptors (notably MC4R) and is used as a research reagent for in vitro study of melanocortin receptor pharmacology and signaling. Supplied as a lyophilized powder for laboratory research use only; not for human or animal use.
These references are provided for research purposes only. Citations do not imply endorsement or approval of this product for any specific application.
